Linked Data API
Show Search Form
Search Results
 |
human indexable |  |
 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
published | |
|
||||||||
|
registered interest |  |
|
||||||||
|
answer date |   |
|||||||||
|
date | |
|||||||||
|
date tabled | |
|||||||||
|
ddp created |  |
|||||||||
|
answering body |
|
|||||||||
|
question status | Tabled | |
||||||||
|
answering dept id | 11 | |
||||||||
 |
answering dept short name | Defence | |
||||||||
|
answering dept sort name | Defence | |
||||||||
|
ddp modified |
|
|||||||||
|
hansard heading | Malaria: Drugs | |
||||||||
|
house id | 2 | |
||||||||
|
identifier | HL16837 | |
||||||||
|
legislature |
|
|||||||||
|
parliament number | 57 | |
||||||||
|
question first answered |
|
|||||||||
|
question text | To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General’s 2016–17 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events. | |
||||||||
|
session |
|
|||||||||
|
session number | 1 | |
||||||||
|
tabling member printed |
|
|||||||||
|
title | House of Lords Tabled Parliamentary Question 2017/19 HL16837 | |
||||||||
|
type |
|
|||||||||
|
uin | HL16837 | |
||||||||
|
version | 3 | |
||||||||
|
written parliamentary question type | Ordinary | |
||||||||
|
answer | answer | |||||||||
|
creator |
|
|||||||||
|
publisher | 25277 | |||||||||
|
tabling member |
|
|||||||||
